IC results in NSCLC should not be extrapolated to more immunogenic cancers such as UC, where there are generally higher proportions of patients with high IC PD-L1 expression (e.g. in the study by Massard et al. using the VENTANA SP263 assay, 45% of screened UC patients were found to be PD-L1-positive on the basis of IC expression, using a 25% cut-off [38]). The gene discussed is CD274; the disease is cancer.